Pneumocystis carinii dihydropteroate synthase mutations and treatment with sulfa or sulfone regimens: a proposal for standardized definitions for clinical evaluation.
Huang
L
L
Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, 94110, USA. lhuang@php.ucsf.edu
Morris
A M
AM
Beard
C B
CB
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis / Q000592:standards; D003622:Dapsone / Q000627:therapeutic use*; D004094:Dihydropteroate Synthase / Q000235:genetics*; D006801:Humans; D009154:Mutation; D011010:Pneumocystis / Q000187:drug effects / Q000201:enzymology / Q000235:genetics; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D017211:Treatment Failure; D016896:Treatment Outcome; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use*
D000890:Anti-Infective Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D003622:Dapsone; D004094:Dihydropteroate Synthase